Millipore Sigma Vibrant Logo

HND3MAG-39K MILLIPLEX MAP Human Neurological Disorders Magnetic Bead Panel 3 - Neuroscience Multiplex Assay

The analytes available for this multiplex kit are: AGT, Contactin-1, Fetuin A, Kallikrein-6, OPN, sSOD1, sSOD2

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Research Category: Neuroscience Key Applications: Multiplexing Detection Methods: Luminex xMAP
HND3MAG-39K
Design And Price Your Kit

Overview

Replacement Information

Key Spec Table

Analytes AvailableSpecies ReactivityKey ApplicationsDetection Methods
Angiotensinogen (AGT), Contactin-1, Fetuin A, Kallikrein-6, Osteopontin (OPN), Soluble Superoxide Dismutase 1 (SOD1), Soluble Superoxide Dismutase 2 (SOD2)HMplexLuminex xMAP
Description
Catalogue NumberHND3MAG-39K
Trade Name
  • MILLIPLEX
DescriptionMILLIPLEX MAP Human Neurological Disorders Magnetic Bead Panel 3 - Neuroscience Multiplex Assay
OverviewThe MILLIPLEX® MAP Human Neurological Disorders Magnetic Bead Panel 3 (Cat. No. HND3MAG-39K) is to be used for the simultaneous quantification of the following 7 analytes in any combination in CSF, serum or plasma samples:

• Angiotensinogen (AGT)
• Contactin-1
• Fetuin A
• Kallikrein-6
• Osteopontin (OPN)
• Soluble Superoxide Dismutase 1 (SOD1)
• Soluble Superoxide Dismutase 2 (SOD2)

NOTE: For serum and plasma samples Fetuin A requires a higher (1:4000) dilution and therefore must be assayed alone as a singleplex. For serum or plasma samples all analytes, except Fetuin A, require a 1:50 dilution and may be assayed together as a multiplex.
Background InformationNeurological disorders are diseases of the brain, spinal cord and nerves. There are more than 600 diseases of the nervous system, such as Multiple sclerosis (MS), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and stroke as well as frontotemporal dementia and many others. Identification of biomarkers for these neurological disorders allows scientists to identify early signs of neurological damage, track disease progression, and monitor efficacy of therapeutic treatment.

The MILLIPLEX® MAP 7-plex Human Neurological Disorders Magnetic Bead Panel 3 is designed for the simultaneous measurement of multiple biomarkers in human cerebrospinal fluid (CSF), plasma, and serum using the Luminex xMAP® instrument platform. The kit contains enough material to analyze 38 samples in duplicate, including the standard curve and two quality controls.

NOTE: For serum and plasma samples Fetuin A requires a higher (1:4000) dilution and therefore must be assayed alone as a singleplex. For serum or plasma samples all analytes, except Fetuin A, require a 1:50 dilution and may be assayed together as a multiplex.
References
Product Information
Detection methodLuminex xMAP
ConfigurationDesign your multiplex kit by choosing available analytes within this panel.
Precision, %
  • Intra-assay: < 10
  • Inter-assay: < 15
Panel TypeMAGNETIC Neuroscience
Quality LevelMQ200
Applications
ApplicationThe analytes available for this multiplex kit are: AGT, Contactin-1, Fetuin A, Kallikrein-6, OPN, sSOD1, sSOD2
Key Applications
  • Multiplexing
Application Notes• This assay requires 25 µL diluted sample per well, sample dilution recommendations are as follows:
o CSF samples: 1:100 dilution in kit Assay Buffer for all analytes.
o Serum and Plasma samples: 1:50 dilution in kit Assay Buffer for all analytes except Fetuin A.
NOTE: Fetuin A cannot be assayed along with other analytes in serum/plasma samples. Fetuin A should be diluted 1:4000 in the kit Assay Buffer and analyzed as a singleplex for serum and plasma samples.
• An overnight (4°C) incubation is recommended (a 2 hour room temperature protocol has also been validated and is included in the protocol)
Biological Information
Species Reactivity
  • Human
Analytes Available
  • Angiotensinogen (AGT)
  • Contactin-1
  • Fetuin A
  • Kallikrein-6
  • Osteopontin (OPN)
  • Soluble Superoxide Dismutase 1 (SOD1)
  • Soluble Superoxide Dismutase 2 (SOD2)
Assay PanelEverything you need in a single kit.
Cross ReactivityThere was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes in this panel.
Accuracy
  • Cerebrospinal fluid (CSF): 69% - 92%
  • Serum: 71% - 107%
Physicochemical Information
Sensitivity
  • Refer to kit protocol for sensitivities of individual biomarkers.
Standard Curve Range
  • AGT: 1.37 – 1,000 ng/mL
  • Contactin-1: 0.08 – 60 ng/mL
  • Fetuin A: 4.12 – 3,000 ng/mL
  • Kallikrein-6: 0.04 – 30 ng/mL
  • Osteopontin (OPN): 0.14 – 100 ng/mL
  • SOD1: 0.04 – 30 ng/mL
  • SOD2: 0.03 – 25 ng/mL
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsRecommended storage for kit components is 2 - 8°C.
Packaging Information
Material Size96-well plate
Transport Information
Supplemental Information
Specifications

Documentation

Protocols

Title
Protocol: Human Neurological Disorders Magnetic Bead Panel 3

MILLIPLEX MAP Human Neurological Disorders Magnetic Bead Panel 3 - Neuroscience Multiplex Assay SDS

Title

Safety Data Sheet (SDS) 

Brochure

Title
A closer look at immunoassay platforms. Beyond fit for purpse. Bring your biomarkers to life with Merck Millipore Immunoassay Platform Solutions.
Custom Immunoassay Menu of Services
The Power of Biomarker Analysis

Technical Info

Title
96 well Template 2 Up
96 well Template Single
Quality Control Ranges: Human Neurological Disorders Magnetic Bead Panel 3

Data Sheet

Title
Full Service Custom-built Assays (Merck)

Posters

Title
MILLIPLEX MAP: Exercise, Signaling, and Your Brain
Inflammation in Neurodegenerative Diseases
Toxicology in drug discovery and development: Biomarkers and model organisms